CNRS Technologies

Find the best CNRS technologies to boost your innovative project.

Les brevets les plus récents

You are a research scientist?

We can guide you through the whole technology transfer process.

See all our services

You are a corporate player?

Thanks to our expertise, our network and our know-how of the innovation ecosystem, we support you throughout your project.

Contact us

Follow our news and upcoming events

Discover CNRS technologies

Meet our team

Fermer

A novel methodology to predict the response to HER2 bloking agent treatment in cancer

Référence

04327-01

Statut des brevets

Priority patent application FR1155128 filed on June, 10th, 2011, entitled “Méthode de prédiction de la réponse à un traitement avec un agent bloquant HER2”

Inventeurs

Gilles PAGES

Statut commercial

Exclusive or non-exclusive licenses, Collaborative agreement

Laboratoire

Institut de biologie du développement et cancer (IBDC), a CNRS laboratory (UMR6543) in Nice, France, http://www.unice.fr/isdbc

Description

CONTEXT

The transmembrane receptor protein HER2 has a tyrosine kinase activity and is involved in the regulation of several genes linked to the transcription of cell cycle. HER2 is overexpressed in several types of cancer, as breast, ovary, colon, pancreas…

This protein is a well known target for anticancer treatments as Trastuzumab, a monoclonal antibody, HER2 bloking agent.

HER2 positive breast cancer show different responses to a trastuzumab treatment. In several cancer cases, Trastuzumab is not indicated to treat the tumor. Indeed, medical centers try to adapt the treatment according to preliminary pronostic on the response of each patient to a HER2 blocking agent treatment.

This prognostic can be done by the characterization of each patient tumoral genes expression profile, from 4 to 28 genes on tumor biopsy. This method is long, expensive and implies a biopsy.

TECHNICAL DESCRIPTION

The inventor has settled a novel methodology to predict each patient response to a HER2 blocking agent treatment. This methodology is based on a surprising discovery on connections between the negative response to Trastuzumab and the silent germinal polymorphism of a specific gene which down regulates the half-life of mRNA encoding several oncogenes, inflammatory factors and angiogenic factors.

Thisin vitro or ex vivo method comprises 2 steps :

=> The specific nucleotidic polymorphism detection on a biological sample
=> The determination of expression of genes of interest on a biological sample

BENEFITS

This method is related to prediction of treatment efficacy which is not currently available.

First of all it is very simple, fast, reliable, reproducible and relatively cheap compared to actual methods:
– No biopsy of the tumor is necessary (less risk related to this sampling). The analysis is based on a simple blood sample (5 to 10 mL) of the patient.
– Analysis involves simple and common molecular biology techniques.

INDUSTRIAL APPLICATIONS

The main application of this invention is the preliminary prognostic to the response of treatment of a cancer with an HER2 blocking agent. This methodology will help medical centres to adapt HER2 positive cancer treaments.

DEVELOPMENT STAGE

This methodology has been validated by inventors on a breast cancer patient cohort.

 


Besoin de plus d'informations ?

Nous contacter
Fermer

Contactez-nous

  • This field is for validation purposes and should be left unchanged.
Fermer

Les brevets les plus récents